Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 8/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 4/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28670191 | 1.00 | DNM1 (0.48) | DNM1EPHX1ALDH1A1TSHRMEN1 | |
| SCHEMBL10994155 | 0.92 | DNM1 (0.48) | DNM1EPHX1ALDH1A1TSHRMEN1 | |
| SCHEMBL9013813 | 0.92 | DNM1 (0.48) | DNM1EPHX1ALDH1A1TSHRMEN1 | |
| SCHEMBL8050512 | 0.92 | DNM1 (0.48) | DNM1EPHX1ALDH1A1TSHRMEN1 | |
| SCHEMBL8052573 | 0.92 | DNM1 (0.48) | DNM1EPHX1ALDH1A1TSHRMEN1 | |
| SCHEMBL8048707 | 0.92 | DNM1 (0.48) | DNM1EPHX1ALDH1A1TSHRMEN1 | |
| SCHEMBL20160771 | 0.87 | DNM1 (0.40) | DNM1EPHX1ALDH1A1TSHRMEN1 | |
| SCHEMBL10705860 | 0.87 | EPHX1 (0.46) | EPHX1ALDH1A1TSHRCA1CA2 | |
| SCHEMBL466284 | 0.87 | EPHX1 (0.46) | EPHX1ALDH1A1TSHRCA1CA2 | |
| SCHEMBL10520996 | 0.87 | EPHX1 (0.46) | EPHX1ALDH1A1TSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133694-B2 | Analyzing metabolites, binding proteins; cyanoalkylation; competitive binding; immunoassay; kits | IMMUNDIAGNOSTIK AG (DE) | 2012-03-13 | — | — | US | disclosed |
| US-20050014211-A1 | Functional vitamin D derivatives and method of determining 25-hydroxy- and 1alpha, 25-dihydroxy vitamin D | BIOMEDICA GMBH (AT) | 2005-01-20 | — | — | US | disclosed |
| US-6787660-B1 | CYANOETHYLATING 3-HYDROXY GROUP, REDUCING TO AMINE AND LINKING WITH SPACER CONTAINING FUNCTIONAL GROUP; COMPETITIVE PROTEIN BINDING ANALYSIS | IMMUNDIAGNOSTIK AG (DE) | 2004-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014211-A1 | Functional vitamin D derivatives and method of determining 25-hydroxy- and 1alpha, 25-dihydroxy vitamin D | CYP24A1, CYP2R1, VDR | DNM1 3079/4885EPHX1 303/4885ALDH1A1 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.